Nanoparticles Targeting Antigen-Presenting Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for activating the immune system to respond to antigens in a desired manner, such as developing tolerance or rejection, are inefficient and often require systemic drug treatments or biological molecules, which can lead to unwanted immune reactions.
Innovation Solution
Development of nanoparticles with specific surface chemistries that target antigen-presenting cells in lymph nodes, activating the complement system without biological agents, allowing for precise immunotherapy delivery by activating complement through synthetic materials, thereby avoiding immune system conflicts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic drug treatments or biological molecules are used to activate the immune system, then immune response can be achieved, but unwanted immune reactions and inefficiency occur
Solution Approach 1:
The patent segments the immune activation process by using nanoparticles to deliver specific immunotherapeutic agents directly to target cells, rather than using systemic treatments that affect the entire immune system. This localized delivery reduces unwanted immune reactions while maintaining effective immune response activation.
Solution Approach 2:
The patent uses nanoparticles as intermediary carriers to deliver immunotherapeutic agents to antigen-presenting cells. These synthetic nanoparticle mediators avoid the use of biological molecules that trigger unwanted immune reactions, while still achieving effective immune system activation through controlled complement system engagement.
2Stability of the object's composition
If nanoparticles are made larger to improve stability, then they can carry more therapeutic agent, but they cannot effectively migrate to the lymphatic system
Solution Approach 1:
The patent optimizes the nanoparticle size parameter to a specific range (20-70 nm diameter) that balances both stability and lymphatic migration capability. This parameter optimization allows the nanoparticles to remain stable enough to carry therapeutic agents while being small enough to effectively migrate through the lymphatic system to reach antigen-presenting cells.
3Reliability
If biological molecules are used to activate complement, then immune activation occurs, but immune system conflicts and cross-reactions occur
Solution Approach 1:
The patent employs synthetic nanoparticle materials that are not recognized by the immune system as foreign biological entities. These synthetic materials can temporarily activate the complement system to achieve immune activation without triggering the immune system's defense mechanisms, cross-reactions, or rejection responses that would occur with biological molecules.
Solution Approach 2:
The patent uses composite nanoparticle structures combining synthetic polymers with immunotherapeutic agents. This composite approach allows the synthetic material carrier to activate complement without causing immune conflicts, while the incorporated therapeutic agents provide the desired immunomodulatory effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles effectively deliver therapeutic agents to antigen-presenting cells in lymph nodes, inducing desired immune responses without triggering unnecessary immune reactions, such as TNF-alpha or IL-6 production, and achieving efficient antigen presentation and immune activation.
Implementation Method 1
the first polymer is free of naturally-occurring biomolecules that activate complement, and the first polymer is strongly bound to the second polymer
Data Source
Figure 1A~1C
Figure 2
Figure 3A~3C
AI summary
Nanoparticles that activate complement in the absence of biological molecules are described. The nanoparticles are shown to specifically target antigen presenting cells in specifically in lymph nodes, without the use of a biological molecule for targeting. These particles are useful vehicles for delivering immunotherapeutics. Surface chemistries and chemical formulations for the nanoparticles are described.